Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — FY2019 Earnings Presentation
28 slides from Pt Prodia Widyahusada Tbk's earnings presentation, March 2020
Slide 1: FY 2019 Results Update
FY 2019 Results Update March 2020 prodia.co.id This presentation has been prepared specifically by Prodia. The content of this presentation may not be used, duplicated or transmitted in any form without the written consent from Prodia. All rights reserved.
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
List of Figures Market & Business Highlights 04 Business & Financial Updates 20 Healthcare & Diagnostic Market 05 New Outlets added in FY2019 21 Market Share 06 Revenue 22 Esoteric Testing Market 07 Quarterly Revenue 23 Genetic Testing Market 08 E-Prodia 24 Services & Customer Segments 09 Gross Prof
Slide 4: Market & Business Highlights
Market & Business Highlights 4
Slide 5: Growing Market for the Healthcare and Diagnostic Lab Sector
Growing Market for the Healthcare and Diagnostic Lab Sector Indonesian Healthcare Market is Growing Indonesia Diagnostic Lab Forecasting Market size by revenue; In USD Billion Market size by revenue; In IDR Trillion 12A-15E 16F-19F 13 15 17 20 22 25 27 CAGR -1.3% CAGR 7.7% 38 5 5 34 4 31 4 10 29 4 9
Slide 6: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Independent Clinical Labs (2017 & 2018) 38.7% 38.8% 29.0% 2017 28.2% 2018 32.3% 33.0% Source: IQVIA Analysis (2019) Note: Next 5 Players consists of: 1) Kimia Farma, 2) Pramita, 3) Parahita, 4) BioMedika , 5)
Slide 7: Potential Growth for Esoteric & Genetic Testing
Potential Growth for Esoteric & Genetic Testing Esoteric Testing Market Global Statistic Regional Outlook Market 2025 Regional CAGR Industry >$39Bn Share (2019-2025) Value by (2018) >9.8% 2025 2024 35% $3.1Bn GLOBAL Germany MARKET SHARE 2022 United States China CAGR 2019-2025 2020 10.1% 2018 $20.8Bn
Slide 8: Potential Growth for Esoteric & Genetic Testing
Potential Growth for Esoteric & Genetic Testing Genetic Testing Market Global Statistics Regional Outlook Market 2025 Regional CAGR Industry >$25Bn Share (2019-2025) >12% Value by (2018) 2024 2025 59% Europe $1.5Bn GLOBAL MARKET SHARE 2022 North America Asia Pacific CAGR 2019-2025 2020 >11.9% 2018 $
Slide 9: Comprehensive Service Offering
Comprehensive Service Offering Targets Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation Predictive, Preventive, General Medical Preventive Treatment Personalized Package Check-Up Services Testing Walk-In Cu
Slide 10: Prodia Laboratories
Prodia Laboratories Indonesian Pioneer in Clinical Laboratory Testing Received SMK3 accreditation and OHSAS 2015, along Established with the Award as "Diagnostic Services Company of the professional Year 2015" from Frost & Sullivan 2019 management team Opened the first green building used for labora
Slide 11: Scalable Hub and Spoke Model
Scalable Hub and Spoke Model Significant Economies of Scale Achieved Prodia Clinical Labs, Centralized information Hospitals and Other Prodia Referral with integrated IT “Hub and spoke” model Clinics may refer tests to Lab Services platform that connects offers scalable platform PRLS (PRLS) each lab
Slide 12: 2019 Awards
2019 Awards WOW Brand Award 2019 Service Quality Award 2019 Corporate Image Award 2019 from Markplus Inc. from Carre Service Quality Monitoring from Frontier Consulting Group & Marketing Magazine Top Brand Award 2019 Social Media Award 2019 Digital Marketing 2019 Indonesia Best from Frontier Consult
Slide 13: Senior Leadership and Management Team
Senior Leadership and Management Team Experienced, Professional Management Team with a Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 47 Experience 47 Experience 37 Experience 31 Experience 33 Experience Andi Gunawan Endang Scott Andrew Lukas S
Slide 14: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 15: Growth Strategy
all Growth Strategy
Slide 16: Growth Strategy
Growth Strategy A Near-term B Long-term Expand our presence and grow Focus on the development of next- our network of outlets in both generation diagnostic existing and new markets in technologies for precision medicine Indonesia Upgrade existing clinical laboratories to provide wider range of tests
Slide 17: Near Term Growth Plan
Near Term Growth Plan Prodia’s Network Expansion Plan 2016 - 2021 1 2 3 4 Expand Network Upgrade Clinical Enhance Operating Focus on of Outlets Labs Efficiency Quality 31 regional referral labs Upgrade up to 39 clinical labs to PHC3 Clinics Up to 33 additional clinical labs over next five years 24 C
Slide 18: FY2016-2019 Total Outlets & FY2020 Development Targets
Business Updates FY2016-2019 Total Outlets & FY2020 Development Targets 129 118 9 2 FY2016 259 Outlets Clinical Labs POC Outlets Hospital Labs Specialty Clinic 136 130 11 5 FY2017 283 Outlets Clinical Labs POC Outlets Hospital Labs Specialty Clinic 143 128 14 7 FY2018 292 Outlets Clinical Labs POC O
Slide 19: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 20: FY2019 Business & Financial Updates
FY2019 Business & Financial Updates 20
Slide 21: New Clinical Labs & Clinic FY2019
Business Updates New Clinical Labs & Clinic FY2019 Clinical Lab, Clinical Lab, Clinical Lab, 6 Mangga Besar, 7 Taman Palem, 2 Tangerang City, Banten Jakarta Jakarta Feb 2019 Mar 2019 Jun 2019 Nov 2019 Dec 2019 FY2019 287 outlets 34 provinces 126 cities 147* Clinical Labs *incl. 5 PHCs Clinical Lab,
Slide 22: FY2019 Revenue (Audited)
Business Updates FY2019 Revenue (Audited) Revenue (in IDR Billion) FY15-FY18 CAGR +10.1% g+9.0% 1,744.3 1,599.8 1,359.0 1,466.0 Visit and volume 1,197.7 expansion continue to support top line growth 2015 2016 2017 2018 2019 22
Slide 23: Quarterly Revenue Trends (Audited)
Business Updates Quarterly Revenue Trends (Audited) Quarterly Revenue 2016 – 2019 (in IDR Billion) 550 Q4, 2019, 505.4 500 Q3, 2019, 439.8 Quarterly revenue 450 Q1 2019, Q2, 2019 2019 illustrates seasonality 399.5 399.6 2018 in the business that is 400 affected by different 2017 variables each quart
Slide 24: Technology to increase Customer Satisfaction
Business Updates Technology to increase Customer Satisfaction Online Order Online Results via Prodia Mobile via Prodia Mobile 24
Slide 25: FY2019 Gross Profit & Net Income (Audited)
Financial Updates FY2019 Gross Profit & Net Income (Audited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) Growth +10.5% Growth +10.5% Growth +16.3% Growth +19.8% 250.0 20.0% 210.3 200.0 175.5 150.8 15.0% 942.8 1,041.0 150.0 853.5 100.0 12.1% 10.0% 59.7% 10.3% 11.0% 58.2% 58.9% 50.0 - 5.
Slide 26: FY2019 COGS & OPEX (Audited)
Financial Updates FY2019 COGS & OPEX (Audited) COGS (in IDR Billion) OPEX (in IDR Billion) CAGR 2015-2018 +8.7% g+7.0% CAGR 2015-2018 +8.3% g +7.4% 703.31,00050.0% 65.0% 656.9 827 612.5 770 565.0 126 800 676 713 50 60.0% 511.0 114 46 101 607 41 90 45.0% 36 39 600 55.0% 82 42.7% 400 50.0% 41.6% 41.8%
Slide 27: Financial Summary FY2019 (Audited)
Financial Updates Financial Summary FY2019 (Audited) (in IDR Bn) FY2019 FY2018 Change Revenue 1,744.3 1,599.8 + 9.0% Gross Profit 1,041.0 942.8 + 10.5% EBIT 216.0 179.9 + 20.1% EBT 264.8 221.7 + 19.4% Net Income 210.3 175.5 + 19.8% EPS 224.3 187.2 + 19.8% EBITDA 316.0 277.5 + 13.9% EBITDA % 18.1% 17
Slide 28: Thank You
Thank You For more information : PT Prodia Widyahusada Tbk Investor.Relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150, Jakarta 10430, Indonesia Phone +6221.3144182 ext. 3774, 3775 http://www.prodia.co.id 1500-830 e-prodia @prodia_lab Laboratorium Klinik Prodia prodia.co.id